GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

Kyung Soo Hong; June Hong Ahn; Jong Geol Jang; Jong Ho Lee; Hong Nam Kim; Dongha Kim; Wonhwa Lee

doi:10.1038/s41392-020-00391-5

GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

Kyung Soo Hong
, June Hong Ahn
, Jong Geol Jang
, Jong Ho Lee
, Hong Nam Kim
, Dongha Kim
, Wonhwa Lee

Department of Anatomy

Yeungnam University
Korea Institute of Science and Technology
University of Science and Technology UST
Korea Research Institute of Bioscience and Biotechnology

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English
Article number	267
Journal	Signal Transduction and Targeted Therapy
Volume	5
Issue number	1
DOIs	https://doi.org/10.1038/s41392-020-00391-5
State	Published - Dec 2020

Bibliographical note

Funding Information:
We thank the patients who participated in this study. This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1A4A4079817 (to W.L.) and 2019R1C1C1004022 (to D.K.)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41392-020-00391-5

Cite this

@article{e19cc04c2ff3400ba36e77f6d8b62b6c,

title = "GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro",

author = "Hong, \{Kyung Soo\} and Ahn, \{June Hong\} and Jang, \{Jong Geol\} and Lee, \{Jong Ho\} and Kim, \{Hong Nam\} and Dongha Kim and Wonhwa Lee",

note = "Funding Information: We thank the patients who participated in this study. This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1A4A4079817 (to W.L.) and 2019R1C1C1004022 (to D.K.)",

year = "2020",

month = dec,

doi = "10.1038/s41392-020-00391-5",

language = "English",

volume = "5",

journal = "Signal Transduction and Targeted Therapy",

issn = "2095-9907",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

AU - Hong, Kyung Soo

AU - Ahn, June Hong

AU - Jang, Jong Geol

AU - Lee, Jong Ho

AU - Kim, Hong Nam

AU - Kim, Dongha

AU - Lee, Wonhwa

N1 - Funding Information: We thank the patients who participated in this study. This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1A4A4079817 (to W.L.) and 2019R1C1C1004022 (to D.K.)

PY - 2020/12

Y1 - 2020/12

UR - https://www.scopus.com/pages/publications/85096098115

U2 - 10.1038/s41392-020-00391-5

DO - 10.1038/s41392-020-00391-5

M3 - Letter

C2 - 33203839

AN - SCOPUS:85096098115

SN - 2095-9907

VL - 5

JO - Signal Transduction and Targeted Therapy

JF - Signal Transduction and Targeted Therapy

IS - 1

M1 - 267

ER -

GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this